首页> 外国专利> Predicting responsiveness of a subject with breast cell proliferative disorder, useful for treating or differentiating breast cell proliferative disorders comprises analyzing methylation pattern of a genomic DNA from the subject

Predicting responsiveness of a subject with breast cell proliferative disorder, useful for treating or differentiating breast cell proliferative disorders comprises analyzing methylation pattern of a genomic DNA from the subject

机译：预测患有乳腺细胞增生性疾病的受试者的反应性，可用于治疗或区分乳腺细胞增生性疾病，包括分析该受试者的基因组DNA的甲基化模式

页面导航

摘要
著录项
相似文献

摘要

Predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues to a therapy comprising analyzing the methylation pattern of a target nucleic acid by contacting at least one of the target nucleic acids in a biological sample obtained from the subject prior to or during treatment, is new. Predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues to a therapy comprising analyzing the methylation pattern of a target nucleic acid by contacting at least one of the target nucleic acids in a biological sample obtained from the subject prior to or during treatment, is new. The therapy for the cell proliferative disorder of the breast tissues comprises one or more drugs, which target the estrogen receptor pathway or are involved in estrogen metabolism, production, or secretion. The target nucleic acid comprises one or a combination of genes selected from STMN1, SFN, S100A2, TGFBR2, TP53, PTGS2, FGFR1, SYK, PITX2, GRIN2D, PSA, CGA, CYP2D6, MSMB, COX7A2L, VTN, PRKCD, ONECUT2, WBP11, CYP2D6, DAG1, ERBB2, S100A2, TFF1, TP53, TMEFF2, ESR1, SYK, RASSF1, PITX2, PSAT1, CGA or PCAF and/or their regulatory regions. Independent claims are also included for the following: (1) a nucleic acid consisting essentially of a sequence at least 18 bases in length selected from 132, 28, 16, 40 or 64 sequences (all sequences not given in the specification) or its complementary sequences; (2) an oligomer, preferably an oligonucleotide or peptide nucleic acid (PNA)-oligomer consisting essentially of at least one base sequence having at least 10 nucleotides which hybridizes to or is identical to one of the nucleic acid sequences above; (3) a set of oligomers comprising at least two oligomers; (4) manufacturing an arrangement of different oligomers (array) fixed to a carrier material for predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues to a therapy; (5) an arrangement of different oligomers (array) obtained from the method above; (6) an array of different oligonucleotide- and/or PNA-oligomer sequences, where the oligonucleotides are arranged on a plane solid phase in the form of a rectangular or hexagonal lattice; (7) a DNA- and/or PNA-array for predicting breast cell proliferative disorders' response to therapy comprising one or more drugs which target the estrogen receptor pathway or are involved in estrogen metabolism, production, or secretion by analysis of the methylation state of any of the CpG dinucleotides selected from 23 sequences (not given in the specification) and comprising at least one nucleic acid given above; and (8) a kit comprising a bisulfite (=disulfite, hydrogen sulfite) reagent as well as oligonucleotides and/or PNA-oligomers.

机译：预测患有乳腺组织细胞增生性疾病的受试者对治疗的反应性，该方法包括通过在从受试者获得的生物学样品中或之前或期间接触靶核酸中的至少一种来分析靶核酸的甲基化模式。治疗，是新的。预测患有乳腺组织细胞增生性疾病的受试者对治疗的反应性，该方法包括通过在从受试者获得的生物学样品中或之前或期间接触靶核酸中的至少一种来分析靶核酸的甲基化模式。治疗，是新的。乳腺组织细胞增殖性疾病的治疗方法包括一种或多种靶向雌激素受体途径或参与雌激素代谢，产生或分泌的药物。靶核酸包含选自以下的一种或多种基因的组合：STMN1，SFN，S100A2，TGFBR2，TP53，PTGS2，FGFR1，SYK，PITX2，GRIN2D，PSA，CGA，CYP2D6，MSMB，COX7A2L，VTN，PRKCD，ONECUT2，WBP11 ，CYP2D6，DAG1，ERBB2，S100A2，TFF1，TP53，TMEFF2，ESR1，SYK，RASSF1，PITX2，PSAT1，CGA或PCAF和/或其调节区域。还包括以下方面的独立权利要求：（1）基本上由长度为至少132个碱基的序列组成的核酸，所述序列选自132、28、16、40或64个序列（说明书中未给出所有序列）或其互补序列顺序; （2）寡聚物，优选寡核苷酸或肽核酸（PNA）-寡聚物，其基本上由至少一个具有至少10个核苷酸的碱基序列组成，所述碱基序列与上述核酸序列之一杂交或相同; （3）一组至少包含两个低聚物的低聚物; （4）制造固定在载体材料上的不同寡聚物（阵列）的排列，用于预测患有乳腺组织细胞增生性疾病的受试者对疗法的反应性; （5）由上述方法获得的不同的低聚物（阵列）的排列; （6）不同寡核苷酸和/或PNA-寡聚物序列的阵列，其中寡核苷酸以矩形或六边形格子的形式排列在平面固相上; （7）一种DNA和/或PNA阵列，用于预测乳腺癌细胞增生性疾病对治疗的反应，其包含一种或多种靶向雌激素受体途径或参与甲基化状态分析的参与雌激素代谢，产生或分泌的药物选自23个序列（说明书中未给出）的任何CpG二核苷酸，其包含至少一个以上给出的核酸; （8）试剂盒，其包含亚硫酸氢盐（＝亚硫酸氢盐，亚硫酸氢盐）试剂以及寡核苷酸和/或PNA-低聚物。

著录项

公开/公告号DE10245779A1

专利类型
公开/公告日2004-04-29

原文格式PDF
申请/专利权人 EPIGENOMICS AG;
展开▼

申请/专利号DE2002145779
发明设计人 KOENIG THOMAS;MAIER SABINE;SCHMITT MANFRED;FOEKENS JOHN;RUJAN TAMAS;MODEL FABIAN;HARBECK NADIA;NIMMRICH INKO;SCHMITT ARMIN;HOEFLER HEINZ;MARTENS JOHN;
展开▼

申请日2002-10-01
分类号C07H21/00;C12Q1/68;C07K14/435;C12N15/11;
国家 DE
入库时间 2022-08-21 22:43:54

相似文献

专利
外文文献
中文文献